Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Five9 Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Five9 Inc trades at $31.2 (market cap $2.44B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.9× Five9 Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| BIO | FIVN | |
|---|---|---|
Market Cap | $9.43B | $2.44B |
Sector | Health | Technology |
52-Week High | $362.08 | $34.48 |
52-Week Low | $241.71 | $13.61 |
Enterprise Value | $9.18B | $2.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Five9 (FIVN) trades at $31.14, down 9.69% today but remains near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to 10% in Q2 2026, reaching $312.4 million, while the company maintains a solid gross margin of 54.91%. Recent management appointments and AI-driven subscription growth provide positive catalysts.
The outlook remains positive with 61% analyst buy ratings and a $32.67 consensus target offering 5% upside. However, elevated valuation multiples (P/E 47.99) and ongoing fiduciary investigations pose risks. The stock's trajectory depends on continued execution of AI revenue growth and margin expansion targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
